Universe Pharmaceuticals (UPC) surged 349% on Nasdaq after a $10.75M patent acquisition deal. The Q3 2026 close carries execution risk with a wide gap between deal price and market cap.
Alpha Score of 41 reflects weak overall profile with moderate momentum, poor value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Universe Pharmaceuticals (UPC) hit the Nasdaq top percentage gainer list Monday, trading at $13.31 after a 349% surge on 41 million shares. The stock touched a morning high of $17.96 before pulling back.
The move follows Friday's announcement that UPC entered a share purchase agreement to acquire Best Praise International Limited for $10.75 million. The price will be paid in 4,376,552 Class A ordinary shares.
Best Praise holds five patents in China covering age-related diseases, neurodegenerative conditions, cognitive disorders, cardiovascular applications, antibacterial compounds, and drug delivery technologies. CEO Gang Lai said the acquisition aligns with the company's long-term strategy of expanding its pharmaceutical platform around elderly healthcare.
UPC specializes in traditional Chinese medicine derivatives targeting elderly patients. The company distributes biomedical drugs, medical instruments, and dietary supplements across 30 Chinese provinces. The patent portfolio is meant to complement that existing focus on geriatric care.
The transaction has board approval and is expected to close in the third quarter of 2026. The share purchase agreement was filed as an exhibit to a Form 6-K with the SEC.
Before the surge, UPC's market capitalization sat below $10 million. At $13.31, it reached roughly $60 million. The acquisition price was $10.75 million. No revenue or licensing agreements tied to the patents have been disclosed.
The stock's previous float was thinly traded. Monday's volume of 41 million shares signaled retail interest rather than institutional buying. The closing of the deal in Q3 2026 is the next scheduled milestone. There is no guarantee the transaction will close on the announced terms or timeline.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.